文献速递慢性肾脏病遗传性与小管间质肾病

TWEAK信号通路阻断减缓常染色体显性多囊肾病囊肿生长与疾病进展

TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2021-06-21

本研究探讨TWEAK信号通路在常染色体显性多囊肾病(ADPKD)中的作用。发现ADPKD患者尿液和囊液中TWEAK显著升高,小鼠模型肾脏囊肿过表达TWEAK和Fn14。抗TWEAK抗体可显著减缓ADPKD进展、保护肾功能并改善生存,其机制与减少细胞增殖相关MAPK信号、NF-κB活化及间接减少巨噬细胞募集有关。

要点

  • ADPKD患者尿液和囊液中TWEAK显著升高,提示其作为生物标志物潜力。
  • 抗TWEAK抗体在 murine ADPKD 模型中减缓囊肿生长、保护肾功能并改善生存。
  • TWEAK通路阻断减少细胞增殖相关MAPK信号和NF-κB活化,间接减少巨噬细胞募集。

核心结论

  • TWEAK信号通路是ADPKD囊肿发生和生长的新的疾病机制,可能成为新的治疗靶点。

研究设计与样本

  • 研究评估了人类和小鼠ADPKD模型中Fn14的表达,并通过腹腔注射探索TWEAK通路激活和抑制对囊肿的影响。
  • 对已发表的囊肿动物模型数据进行荟萃分析,显示TWEAK通路多个组分的mRNA上调。

主要发现

  • 小鼠ADPKD肾脏囊肿中TWEAK和Fn14过表达,ADPKD患者尿液和囊液中TWEAK显著升高。
  • TWEAK给药诱导囊肿发生并增加囊肿生长,恶化小鼠ADPKD模型表型。
  • 抗TWEAK抗体显著减缓ADPKD进展,保护肾功能,改善生存。
  • 抗TWEAK减少囊肿发生与细胞增殖相关MAPK信号降低、NF-κB通路活化减少、纤维化和凋亡轻度减少以及巨噬细胞募集间接减少有关。

临床怎么用

  • 抗TWEAK抗体可能成为ADPKD的新治疗策略,但需进一步临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), cyst development and enlargement lead to ESKD. Macrophage recruitment and interstitial inflammation promote cyst growth. TWEAK is a TNF superfamily (TNFSF) cytokine that regulates inflammatory responses, cell proliferation, and cell death, and its receptor Fn14 (TNFRSF12a) is expressed in macrophage and nephron epithelia. METHODS: To evaluate the role of the TWEAK signaling pathway in cystic disease, we evaluated Fn14 expression in human and in an orthologous murine model of ADPKD. We also explored the cystic response to TWEAK signaling pathway activation and inhibition by peritoneal injection. RESULTS: Meta-analysis of published animal-model data of cystic disease reveals mRNA upregulation of several components of the TWEAK signaling pathway. We also observed that TWEAK and Fn14 were overexpressed in mouse ADPKD kidney cysts, and TWEAK was significantly high in urine and cystic fluid from patients with ADPKD. TWEAK administration induced cystogenesis and increased cystic growth, worsening the phenotype in a murine ADPKD model. Anti-TWEAK antibodies significantly slowed the progression of ADPKD, preserved renal function, and improved survival. Furthermore, the anti-TWEAK cystogenesis reduction is related to decreased cell proliferation-related MAPK signaling, decreased NF-κB pathway activation, a slight reduction of fibrosis and apoptosis, and an indirect decrease in macrophage recruitment. CONCLUSIONS: This study identifies the TWEAK signaling pathway as a new disease mechanism involved in cystogenesis and cystic growth and may lead to a new therapeutic approach in ADPKD.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cordido A, Nuñez-Gonzalez L, Martinez-Moreno JM, et al. TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2021. PMID: 34155062. doi:10.1681/ASN.2020071094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。